ARTRYA LIMITED (AYA)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AYA

AYA - ARTRYA LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.01
Index: ALL-ORDS | ALL-TECH

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.99

27 Aug
2026

0.210

OPEN

$4.83

4.39%

HIGH

$5.06

543,767

LOW

$4.70

TARGET
$6.75 35.3% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
AYA: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 17.0 - 10.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A N/A xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-17.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx48.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-15.8 M
Net Profit Margin xxxxxxxxxxxxxxx-89,939.29 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-50.58 %
Return on Invested Capital xxxxxxxxxxxxxxx-50.44 %
Return on Assets xxxxxxxxxxxxxxx-46.20 %
Return on Equity xxxxxxxxxxxxxxx-50.58 %
Return on Total Capital xxxxxxxxxxxxxxx-54.34 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-15.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx74 M
Price To Book Value xxxxxxxxxxxxxxx12.70

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx1,785.71 %
Cost of Goods Sold xxxxxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx26 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

20/08/2026

1

Buy

$6.75

35.27%

Artrya enters FY27 with its foundation Salix customer fully onboarded and around $74m in cash, leaving the company well-funded through to Bell Potter's expected breakeven in FY28.

The FY26 operating loss of around -$27.6m was largely as expected and reflects the platform's early commercialisation phase, while net operating cash outflow increased to around -$18m from -$14.3m.

Early customer experience is encouraging, with Tanner Health reporting CCTA interpretation time reductions of around -50%-80%, while NGHS is now onboarded and Cone Health is expected to complete onboarding this quarter.

FY27 is expected to show the repeatability of Salix's workflow benefits and potentially deliver conversion of at least one SAPPHIRE study partner, with initial study data potentially available in 2H calendar 2027.

Target raised to $6.75 from $6.10.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -10.30 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 1.60 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

AYA STOCK CHART

FNArena News on AYA

1
FNArena Corporate Results Monitor – 20-08-2026

Aug 20 2026 - Australia
2
In Brief: Credit Corp, Horizon Minerals & Artrya

Feb 06 2026 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Feb 03, 2026

Feb 03 2026 - Daily Market Reports
4
Rudi’s View: Pre-February Top Picks & Favourites

Jan 15 2026 - Rudi's View
5
Next Week At A Glance – 15-19 Sep 2025

Sep 12 2025 - Weekly Reports

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals